Miner JN - Search Results

1

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A. Schmieder R, et al. Among authors: miner jn. Neoplasia. 2013 Oct;15(10):1161-71. doi: 10.1593/neo.13812. Neoplasia. 2013. PMID: 24204195 Free PMC article.

2

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ Jr, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. Adjei AA, et al. Among authors: miner jn. Clin Cancer Res. 2016 May 15;22(10):2368-76. doi: 10.1158/1078-0432.CCR-15-1681. Epub 2015 Dec 7. Clin Cancer Res. 2016. PMID: 26644411 Free PMC article. Clinical Trial.

3

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Weekes CD, et al. Among authors: miner jn. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22. Clin Cancer Res. 2013. PMID: 23434733 Clinical Trial.

4

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, Hamatake R, Miner JN, Quart B. Iverson C, et al. Among authors: miner jn. Cancer Res. 2009 Sep 1;69(17):6839-47. doi: 10.1158/0008-5472.CAN-09-0679. Epub 2009 Aug 25. Cancer Res. 2009. PMID: 19706763

5

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Chang Q, Chapman MS, Miner JN, Hedley DW. Chang Q, et al. Among authors: miner jn. BMC Cancer. 2010 Sep 28;10:515. doi: 10.1186/1471-2407-10-515. BMC Cancer. 2010. PMID: 20920162 Free PMC article.

6

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Miner JN, et al. Arthritis Res Ther. 2016 Oct 3;18(1):214. doi: 10.1186/s13075-016-1107-x. Arthritis Res Ther. 2016. PMID: 27716403 Free PMC article. Clinical Trial.

7

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S; RDEA594-111 Study Group. Fleischmann R, et al. Among authors: miner jn. Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8. Rheumatology (Oxford). 2014. PMID: 24509406 Clinical Trial.

8

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.

Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, Hall JW. Shen Z, et al. Among authors: miner jn. Drug Des Devel Ther. 2017 Jul 7;11:2077-2086. doi: 10.2147/DDDT.S140658. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28744099 Free PMC article. Clinical Trial.

9

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Miner JN, et al. Arthritis Res Ther. 2016 Oct 12;18(1):236. doi: 10.1186/s13075-016-1150-7. Arthritis Res Ther. 2016. PMID: 27733209 Free PMC article. No abstract available.

10

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.

Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C. Hall J, et al. Among authors: miner jn. Drug Des Devel Ther. 2018 Jun 20;12:1799-1807. doi: 10.2147/DDDT.S152659. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29950814 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters